Prot #GS-US-592-6238: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do N

Project: Research project

Project Details

StatusActive
Effective start/end date1/30/231/30/26

Funding

  • ICON Clinical Research Limited (Prot #GS-US-592-6238 // Prot #GS-US-592-6238)
  • Gilead Sciences, Inc (Prot #GS-US-592-6238 // Prot #GS-US-592-6238)